Treatment Beyond Progression: Is It Moving from Belief to Evidence?

od Yerushalmi, Rinat, Gelmon, Karen
Izdano 2010

Can We Hang Our Hats on One Percent?

od LeVasseur, Nathalie, Gelmon, Karen A.
izdano v Oncologist (2018)

Is Canadian women’s breast cancer screening behaviour associated with having a family doctor?

od Poole, Barbara, Black, Charlyn, Gelmon, Karen, Kan, Lisa
Izdano 2010

Low grade serous carcinoma of the peritoneum in a BRCA1 carrier previously diagnosed with a “low-grade serous tubal intra-epithelial carcinoma” (STIC) on risk reducing surgery

od Chay, Wen Yee, Horlings, Hugo M., Tinker, Anna V., Gelmon, Karen A., Gilks, C.Blake
izdano v Gynecol Oncol Rep (2015)

Gatekeeping in cancer clinical trials in Canada: The ethics of recruiting the “ideal” patient

od Bell, Jennifer A. H., Kelly, Mary T., Gelmon, Karen, Chi, Kim, Ho, Anita, Rodney, Patricia, Balneaves, Lynda G.
izdano v Cancer Med (2020)

The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities

od Teckle Paulos, Peacock Stuart, McTaggart-Cowan Helen, van der Hoek Kim, Chia Stephen, Melosky Barb, Gelmon Karen
Izdano 2011-11-01

The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities

od Teckle, Paulos, Peacock, Stuart, McTaggart-Cowan, Helen, van der Hoek, Kim, Chia, Stephen, Melosky, Barb, Gelmon, Karen
Izdano 2011

Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D

od Teckle, Paulos, McTaggart-Cowan, Helen, Van der Hoek, Kim, Chia, Stephen, Melosky, Barb, Gelmon, Karen, Peacock, Stuart
izdano v Health Qual Life Outcomes (2013)

Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue...

od Crabb, Simon J, Bajdik, Chris D, Leung, Samuel, Speers, Caroline H, Kennecke, Hagen, Huntsman, David G, Gelmon, Karen A
Izdano 2008

HER Story: The Next Chapter in HER-2-Directed Therapy for Advanced Breast Cancer

od Verma, Sunil, Joy, Anil A., Rayson, Daniel, McLeod, Deanna, Brezden-Masley, Christine, Boileau, Jean-François, Gelmon, Karen A.
Izdano 2013

A Longitudinal Study of the Association of Clinical Indices of Cardiovascular Autonomic Function with Breast Cancer Treatment and Exercise Training

od Kirkham, Amy A., Lloyd, Matthew G., Claydon, Victoria E., Gelmon, Karen A., McKenzie, Donald C., Campbell, Kristin L.
izdano v Oncologist (2018)

Prospective Long-Term Follow-Up of Pulmonary Diffusion Capacity Reduction Caused by Dose-Dense Chemotherapy in Patients with Breast Cancer

od Landman, Yosef, Stemmer, Salomon Marcello, Sulkes, Aaron, Neiman, Victoria, Granot, Tal, Hendler, Daniel, Kramer, Mordechai Reuven, Gelmon, Karen, Yerushalmi, Rinat
izdano v J Oncol (2019)

Understanding breast cancer patients' preference for two types of exercise training during chemotherapy in an unblinded randomized controlled trial

od Vallance Jeffrey K, Proulx Caroline, Gelmon Karen, Friedenreich Christine M, Reid Robert D, Courneya Kerry S, McKenzie Donald C, Segal Roanne J
Izdano 2008-10-01

Understanding breast cancer patients' preference for two types of exercise training during chemotherapy in an unblinded randomized controlled trial

od Courneya, Kerry S, Reid, Robert D, Friedenreich, Christine M, Gelmon, Karen, Proulx, Caroline, Vallance, Jeffrey K, McKenzie, Donald C, Segal, Roanne J
Izdano 2008

Effectiveness of Oncologist‐Referred Exercise and Healthy Eating Programming as a Part of Supportive Adjuvant Care for Early Breast Cancer

od Kirkham, Amy A., Van Patten, Cheri L., Gelmon, Karen A., McKenzie, Donald C., Bonsignore, Alis, Bland, Kelcey A., Campbell, Kristin L.
izdano v Oncologist (2017)

Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases

od Rajput, Ashish B., Turbin, Dmitry A., Cheang, Maggie CU, Voduc, David K., Leung, Sam, Gelmon, Karen A., Gilks, C. Blake, Huntsman, David G.
Izdano 2007

Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes

od Habibi, Golareh, Leung, Samuel, Law, Jennifer H, Gelmon, Karen, Masoudi, Hamid, Turbin, Dmitry, Pollak, Michael, Nielsen, Torsten O, Huntsman, David, Dunn, Sandra E
Izdano 2008

QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reduction...

od Kalra, Jessica, Warburton, Corinna, Fang, Karen, Edwards, Lincoln, Daynard, Tim, Waterhouse, Dawn, Dragowska, Wieslawa, Sutherland, Brent W, Dedhar, Shoukat, Gelmon, Karen, Bally, Marcel
Izdano 2009

A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2‐Positive Metastatic Breast Cancer (CCTG IND.229)

od Chia, Stephen, Bedard, Phillipe L., Hilton, John, Amir, Eitan, Gelmon, Karen, Goodwin, Rachel, Villa, Diego, Cabanero, Michael, Tu, Dongsheng, Tsao, Ming, Seymour, Lesley
izdano v Oncologist (2019)

Facilitated “Fast Track” Referral Reduces Time from Abnormal Screening Mammogram to Diagnosis

od Borugian, Marilyn J., Kan, Lisa, Chu, Christina C. Y., Ceballos, Kathy, Gelmon, Karen A., Gordon, Paula B., Poole, Barbara, Tyldesley, Scott, Olivotto, Ivo A.
izdano v Can J Public Health (2008)